The phase III ToGA trial showed that chemotherapy plus Trastuzumab, a HER-2- targeted monoclonal antibody, improved overall survival (13.8 months vs. 11.1 months) and progression-free survival (6.7 months vs. 5.5 months) in patients with these cancers versus chemotherapy alone [7]. This evidence concerns the gene ERBB2 and cancer.